The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications
Longitudinal studies among people with Multiple Sclerosis (pwMS) have shown that self-efficacy is linked to physical, cognitive and psychological functioning. To determine the distribution of self-efficacy in a large sample of pwMS, examining whether there are distinct groups which show different se...
Gespeichert in:
Veröffentlicht in: | Journal of the neurological sciences 2022-05, Vol.436, p.120188-120188, Article 120188 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Longitudinal studies among people with Multiple Sclerosis (pwMS) have shown that self-efficacy is linked to physical, cognitive and psychological functioning.
To determine the distribution of self-efficacy in a large sample of pwMS, examining whether there are distinct groups which show different self-efficacy trajectories over time, and the health status characteristics of any groups identified.
Participants completed serial questionnaire packs, including Unidimensional Self-efficacy-MS (USE-MS) scale, for the Trajectories of Outcome in Neurological Conditions-MS (TONiC-MS) study over an average 46-month period. The resulting longitudinal data were analysed by a group-based trajectory model.
5887 pwMS were studied: mean age 50.2 years (SD 12.0); 73.6% female; Relapsing Remitting MS (61.8%), Secondary Progressive (22.9%), Primary Progressive (11.1%), Rapidly Evolving Relapsing Remitting MS (4.2%). Four distinct self-efficacy trajectories emerged, with declining, slightly declining, stable or improving self-efficacy, each showing different patterns of health status indicators such as EQ-5D-5L, disability and depression. USE-MS ≤ 18 at baseline detected all participants in the two declining groups.
Future trials on interventions for self-efficacy should assume a priori that those with low levels of self-efficacy (USE-MS ≤ 18 at baseline) are likely to be on a declining trajectory and may need different interventions from those with stable self-efficacy.
[Display omitted]
•MS patients (n = 5887) showed distinct self-efficacy trajectories over 4 years of follow-up•Stable, improving and declining trajectories were evident from soon after diagnosis•Each trajectory group had different health characteristics, eg disability, depression•Self-reported USE-MS ≤ 18 score at baseline identified those at risk of declining self-efficacy•Follow-up shows improving self-efficacy is associated with lower reported disability |
---|---|
ISSN: | 0022-510X 1878-5883 |
DOI: | 10.1016/j.jns.2022.120188 |